Jonathan Miller
Stock Analyst at Evercore ISI Group
(n/a)
# 4,706
Out of 5,064 analysts
5
Total ratings
n/a
Success rate
-46.95%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jonathan Miller
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NTLA Intellia Therapeutics | Downgrades: In-Line | $17 → $8 | $8.21 | -2.56% | 1 | Nov 11, 2025 | |
| PROK ProKidney | Initiates: Outperform | n/a | $2.19 | - | 1 | Sep 2, 2022 | |
| TRDA Entrada Therapeutics | Initiates: Outperform | n/a | $10.11 | - | 1 | Nov 24, 2021 | |
| STTK Shattuck Labs | Initiates: Outperform | n/a | $2.03 | - | 1 | Jan 11, 2021 | |
| NBTX Nanobiotix | Initiates: Outperform | n/a | $20.93 | - | 1 | Jan 6, 2021 |
Intellia Therapeutics
Nov 11, 2025
Downgrades: In-Line
Price Target: $17 → $8
Current: $8.21
Upside: -2.56%
ProKidney
Sep 2, 2022
Initiates: Outperform
Price Target: n/a
Current: $2.19
Upside: -
Entrada Therapeutics
Nov 24, 2021
Initiates: Outperform
Price Target: n/a
Current: $10.11
Upside: -
Shattuck Labs
Jan 11, 2021
Initiates: Outperform
Price Target: n/a
Current: $2.03
Upside: -
Nanobiotix
Jan 6, 2021
Initiates: Outperform
Price Target: n/a
Current: $20.93
Upside: -